Ticagrelor Tablet
Product Images NDC 60505-4452

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 60505-4452). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Btl-lbl-90mg-60s.jpg (Btl Lbl 90mg 60s)

This text provides information on a medication containing 90 mg of ticagrelor in film-coated tablets. It includes storage instructions, adult dosage details, and manufacturer information. The tablets should be stored at 20-25°C with excursions permitted to 15-30°C. The manufacturer is Apotex Inc. from Toronto, Ontario, Canada. The medication is manufactured for Apotex Corporation in Weston, Florida. The text advises to keep the medication out of reach of children and includes a mention of a Medication Guide available online for patients.*

FDA Label Image

Figure1.jpg (Figure1)

This text contains data related to a study comparing the efficacy of two drugs, Ti0mg and Clopidogrel, in patients. It shows the number of patients with events, KM % at 12 months, and the number of days from the first study drug dose. The study included 9235 patients for Ti0mg and 9186 patients for Clopidogrel, with results indicating the percentage of patients experiencing events and the patients at risk over specific time points.*

FDA Label Image

Figure10.jpg (Figure10)

This text appears to contain a table with data related to patients with events, Kaplan-Meier percentages at 12 months, Hazard Ratio, and p-value for the comparison between Ticagrelor and Clopidogrel. It also includes the number of days from randomization and the number of patients at risk for each treatment group at different time points. The data suggests a comparison between these two treatments for some clinical outcome.*

FDA Label Image

Figure11.jpg (Figure11)

This text seems to provide detailed information on the characteristics and results of a research study, including data on the treatment effects based on different parameters such as geographic region, treatment approach, age groups, and more. It also includes comparisons between different medications like Ticagrelor and Clopidogrel, presenting outcomes in terms of overall treatment effect and endpoints. The text appears to contain statistical data and confidence intervals for comparison purposes, allowing for an in-depth analysis of the study's findings.*

FDA Label Image

Figure12.jpg (Figure12)

Not available.*

FDA Label Image

Figure13.jpg (Figure13)

This is a comparison of the effectiveness of two different doses of Ti medication and a placebo in a clinical trial over a period of 3 years. The text includes data on the number of patients with events, Kaplan-Meier percentages at 36 months, hazard ratios with confidence intervals, and p-values. The chart displays the number of patients at risk over time for each treatment group.*

FDA Label Image

Figure14.jpg (Figure14)

This data table shows various characteristics and treatment effects of a clinical trial, including groups based on age, weight, geographic region, medical history, and treatment received. The table also presents hazard ratios with corresponding 95% confidence intervals for the comparison of Ticagrelor versus Placebo. The information is organized in a structured format for researchers to analyze and draw conclusions related to the outcomes of the study.*

FDA Label Image

Figure15.jpg (Figure15)

FDA Label Image

Figure16.jpg (Figure16)

This dataset provides characteristics and outcomes of patients in a study comparing Ticagrelor vs. Placebo. The data includes information on demographics, medical history, and treatment outcomes, such as age, sex, race, body mass index, geographic region, baseline health parameters, medical histories (like angina, PCI, and CABG), smoking status, diabetes duration, and more. The study compares the efficacy of Ticagrelor and Placebo in various subgroups based on these characteristics, showing the hazard ratio (HR) with a 95% confidence interval. This information is valuable for understanding how different patient factors might influence the effectiveness of Ticagrelor as compared to Placebo.*

FDA Label Image

Figure17.jpg (Figure17)

This text seems to provide data related to the investigation of Ticagrelor 90 mg compared to Placebo in a clinical trial. It includes information such as the number of events, cumulative percentages, and the number of participants at risk over time. The data suggests a comparison of the efficacy of Ticagrelor and Placebo in the study.*

FDA Label Image

Figure18.jpg (Figure18)

The text provides data on the comparison between Ticagrelor and Placebo in relation to various characteristics including age, sex, race, weight, diagnosis of index event, comorbidities like diabetes mellitus, hypertension, prior stroke or TIA, ischaemic heart disease, ASA and statin treatment, and smoking status. It includes information on the hazard ratio (HR) and confidence intervals (CI) for each comparison. The data is segmented based on different criteria such as age groups, sex, race, weight categories, geographic regions, comorbidities, and prior treatments. The results suggest that Ticagrelor shows potential benefits compared to Placebo in certain subgroups.*

FDA Label Image

Figure2.jpg (Figure2)

The text appears to be a table showing the percentage of patients who had an event following Coronary Artery Bypass Graft (CABG) surgery over different days. The table shows a decreasing trend in the percentage of patients with events over time.*

FDA Label Image

Figure3.jpg (Figure3)

This text provides data on cumulative percentage of events related to ticagrelor and placebo, with the number of events and N at risk over different months from randomization. The table shows the progression of events over time for each treatment group.*

FDA Label Image

Figure4.jpg (Figure4)

This is a statistical table showing the events percentage for Ticagrelor 90 mg bd and Placebo over a specific period. Ticagrelor had an events rate of 0.5% over 28/5523 days, while Placebo had a lower rate of 0.1% over 715493 days. The table also includes information on the number at risk and days from randomization for both treatments.*

FDA Label Image

Figure5.jpg (Figure5)

FDA Label Image

Figure6.jpg (Figure6)

FDA Label Image

Figure7.jpg (Figure7)

This text provides information about the recommended dose adjustments for Ticagrelor AR-CID4010XX based on intrinsic factors such as age, gender, ethnicity, renal impairment, and hepatic impairment. It specifies that there is no dose adjustment required for individuals falling within certain categories or conditions. The text also mentions guidelines for patients with end-stage renal disease on hemodialysis and hepatic impairment. Additionally, there is reference to the change relative to the reference for dosing.*

FDA Label Image

Figure8.jpg (Figure8)

This text indicates interactions of the drug Ticagrelor with various other drugs such as strong CYP3A4 inhibitors like Ketoconazole, moderate CYP3A4 inhibitors like Diltiazem, potent CYP3A4 inducers like Rifampin, and others like Aspirin, Desmopressin, Heparin, and Cyclosporine. It provides recommendations for dosing adjustments and avoiding concomitant use for some medications. The text also mentions specific doses and administration information for certain drugs.*

FDA Label Image

Figure9.jpg (Figure9)

FDA Label Image

Structure.jpg (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.